CYTOKINE-MEDIATED T CELL ACTIVATION
CYTOKINE-MEDIATED T CELL ACTIVATION
批准号:
7958438
负责人:
MARK K SLIFKA
金额:
$8.03万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-04 至 2010-04-30
关键词:
AntigensBacterial InfectionsCD8B1 geneCellsComputer Retrieval of Information on Scientific Projects DatabaseDiseaseFundingGene ExpressionGrantHandImmune responseInflammatoryInstitutionInterferon Type IIInterleukin-12Interleukin-18LearningMediatingPlayPrimatesProductionResearchResearch PersonnelResourcesRestRoleSeptic ShockSignal TransductionSourceSpecificitySymptomsT memory cellT-Cell ActivationT-LymphocyteTimeUnited States National Institutes of HealthVirusantimicrobialcytokineexperienceimmunopathologyresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Virus-specific CD8+ T cells often avoid causing severe immunopathology by strictly regulating their cytokine production and turning cytokine secretion on, off, and on again in response to direct antigen contact. In contrast, interleukin-12 (IL-12) and interleukin-18 (IL-18) represent two potent inflammatory cytokines that trigger interferon-gamma (IFNg) production by activated T cells in the absence of direct antigen contact. Although activated CD8+ T cells are known to respond to IL-12/IL-18 stimulation, the effects of these cytokines on long-term, resting memory T cells is largely unknown and represents a significant gap in our understanding of this phenomenon. In our proposed studies, we will compare and contrast effector and memory T cells of a defined specificity in terms of: 1) cytokine production, 2) cytolytic activity, 3) proliferation, and 4) global gene expression following stimulation with IL-12 and IL-18. This information will be important for understanding how IL-12/IL-18 secretion might be used by infected cells as an intrinsic "danger" signal to trigger antimicrobial immune responses by nearby antigen-experienced T cells without requiring direct TcR stimulation. On the other hand, this loss of antigen specificity also appears to play a substantial role in certain types of T cell-mediated immunopathology associated with secondary bacterial infections and septic shock. For these reasons, a thorough understanding of cytokine-mediated T cell activation is critical for learning how to maintain or augment appropriate T cell responses while at the same time decreasing T cell-associated symptoms of disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of an H2O2-Inactivated Dengue Virus Vaccine
-
批准号:8267908
-
项目类别:
-
资助金额:$132.76万
-
财政年份:2012
-
负责人:MARK K SLIFKA
-
依托单位:
Development of an H2O2-Inactivated Dengue Virus Vaccine
-
批准号:8840142
-
项目类别:
-
资助金额:$151.33万
-
财政年份:2012
-
负责人:MARK K SLIFKA
-
依托单位:
Development of an H2O2-Inactivated Dengue Virus Vaccine
-
批准号:8651871
-
项目类别:
-
资助金额:$148.82万
-
财政年份:2012
-
负责人:MARK K SLIFKA
-
依托单位:
Development of an H2O2-Inactivated Dengue Virus Vaccine
-
批准号:8463114
-
项目类别:
-
资助金额:$158.91万
-
财政年份:2012
-
负责人:MARK K SLIFKA
-
依托单位:
YELLOW FEVER VACCINATION OF THE AGED AND IMMUNOCOMPROMISED
-
批准号:8357801
-
项目类别:
-
资助金额:$5.82万
-
财政年份:2011
-
负责人:MARK K SLIFKA
-
依托单位:
DEVELOPMENT OF A SAFE AND EFFECTIVE VACCINE AGAINST WEST NILE VIRUS
-
批准号:8357802
-
项目类别:
-
资助金额:$10.91万
-
财政年份:2011
-
负责人:MARK K SLIFKA
-
依托单位:
T CELL ACTIVATION AND FUNCTIONAL AVIDITY
-
批准号:8173191
-
项目类别:
-
资助金额:$4.76万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
DEVELOPMENT OF A YELLOW FEVER VACCINE FOR VULNERABLE POPULATIONS
-
批准号:8173258
-
项目类别:
-
资助金额:$4.76万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
YELLOW FEVER VACCINATION OF THE AGED AND IMMUNOCOMPROMISED
-
批准号:8173291
-
项目类别:
-
资助金额:$9.51万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
DEVELOPMENT OF A SAFE AND EFFECTIVE VACCINE AGAINST WEST NILE VIRUS
-
批准号:8173292
-
项目类别:
-
资助金额:$9.51万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
VACCINE-INDUCED CD8+ T CELL MEMORY
-
批准号:8173257
-
项目类别:
-
资助金额:$7.61万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
CYTOKINE-MEDIATED T CELL ACTIVATION
-
批准号:8173199
-
项目类别:
-
资助金额:$7.61万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
VACCINE-INDUCED CD8+ T CELL MEMORY
-
批准号:7958529
-
项目类别:
-
资助金额:$8.03万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
DEVELOPMENT OF A YELLOW FEVER VACCINE FOR VULNERABLE POPULATIONS
-
批准号:7958530
-
项目类别:
-
资助金额:$6.04万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
Development of a new yellow fever vaccine for vulnerable populations
-
批准号:7676346
-
项目类别:
-
资助金额:$26.63万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
Development of a Safe and Effective Vaccine Against West Nile Virus
-
批准号:8238380
-
项目类别:
-
资助金额:$109.74万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
Development of a Safe and Effective Vaccine Against West Nile Virus
-
批准号:7644679
-
项目类别:
-
资助金额:$79.65万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
T CELL ACTIVATION AND FUNCTIONAL AVIDITY
-
批准号:7958426
-
项目类别:
-
资助金额:$8.03万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
Development of a Safe and Effective Vaccine Against West Nile Virus
-
批准号:8054391
-
项目类别:
-
资助金额:$303.98万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
Development of a Safe and Effective Vaccine Against West Nile Virus
-
批准号:7797564
-
项目类别:
-
资助金额:$212.83万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
海外基金